Quick Takeaways
- Redmile Group, LLC filed SCHEDULE 13G/A for ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share (ALXO).
- Disclosed ownership: 6.8%.
- Date of event: 31 Mar 2026.
Redmile Group, LLC - 31 Mar 2026 SCHEDULE 13G/A Report for ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share (ALXO)
- Filing Manager
- Redmile Group, LLC
- Reporting Manager
- Redmile Group, LLC
- Symbol
- ALXO
- Shares outstanding
- 135,502,765 shares
- Disclosed Ownership
- 9,214,188 shares
- Ownership
- 6.8%
- Form type
- SCHEDULE 13G/A
- Filing time
- 15 May 2026, 16:15:41 UTC
- Date of event
- 31 Mar 2026
- Previous filing
- 14 Aug 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Redmile Group, LLC disclosed 6.8% ownership in ALX Oncology Holdings Inc. Common Stock, par value $0.001 per share (ALXO) on 31 Mar 2026."
What Changed
- Previous schedule filing date: 14 Aug 2025.
- Current filing was accepted on 15 May 2026, 16:15.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Source Evidence
Backed by Schedule 13D/13G
See Original Filing
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
Reporting Managers (3)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Redmile Group, LLC | 6.8% | 9,214,188 | 0 | 9,214,188 | /s/ Jeremy C. Green | Managing Member | |
| Jeremy C. Green | 6.8% | 9,214,188 | 0 | 9,214,188 | /s/ Jeremy C. Green | Jeremy C. Green | |
| Redmile Biopharma Investments III, L.P. | 3.9% | 5,267,838 | 0 | 5,267,838 | /s/ Jeremy C. Green | Managing Member of Redmile Biopharma Investments III (GP), LLC, general partner of Redmile Biopharma Investments III, L.P. |